Neurodegeneration

For over 30 years, Eli Lilly and Company has been a global leader for the fight against Alzheimer's disease. Learn more about Lilly's clinical development.

Lilly’s neurodegeneration pipeline is one of the deepest in the industry and is shaped by the discoveries we’ve made over nearly three decades of research and development. Our current programme focuses predominantly on developing disease-modifying therapies that slow or halt the progression of Alzheimer’s disease. We’re also studying ways to treat the symptoms of other forms of dementia. Lilly is honoured to be a part of leading, independent collaborations in the broader Alzheimer’s disease scientific community.

Dementia Discovery Fund:

Lilly is one of the founding members of the Dementia Discovery Fund (DDF), the world’s largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s research. For us, participating in the DDF builds on our company’s own 30-plus year commitment to research in Alzheimer’s disease.